BACKGROUND: Trichomonas vaginalis is the etiological agent of trichomoniasis, the most common non-viral sexually transmitted infection (STI) worldwide. The increasing resistance to metronidazole, currently the only FDA-approved treatment, necessitates the development of a novel vaccine to prevent and control this infection. METHODS: In this study, an in silico immunoinformatics pipeline was employed to identify antigenic peptides and construct a multi-epitope vaccine candidate targeting T. vaginalis. Surface and secretory proteins were retrieved and analyzed for antigenicity, allergenicity, and toxicity. B-cell and T-cell epitopes were predicted using IEDB tools and evaluated based on their binding affinity to common MHC class I and II alleles. Suitable linkers (GPGPG, AAY, EAAAK) and an HBHA adjuvant were incorporated to enhance immunogenicity. RESULTS: The final vaccine construct consisted of 1081 amino acids and demonstrated high antigenicity, non-allergenicity, and non-toxicity. Structural predictions revealed favorable solubility and stability characteristics. Immune simulations indicated strong humoral and cellular immune responses. Population coverage analysis showed broad global applicability, particularly in European populations. CONCLUSION: This in silico designed multi-epitope vaccine shows strong potential as a preventive strategy against T. vaginalis. Further experimental validation through in vitro and in vivo studies is necessary to confirm its immunogenicity and protective efficacy.